We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Luminex Corporation Begins Clinical Trials for ARIES™ GBS Assay
News

Luminex Corporation Begins Clinical Trials for ARIES™ GBS Assay

Luminex Corporation Begins Clinical Trials for ARIES™ GBS Assay
News

Luminex Corporation Begins Clinical Trials for ARIES™ GBS Assay

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Luminex Corporation Begins Clinical Trials for ARIES™ GBS Assay"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Luminex Corporation has announced that it has commenced clinical and analytical studies to evaluate the company's ARIES™ Group B Streptococcus (GBS) Assay.

"We continue to build momentum in our commercial launch schedule for the ARIES platform with the start of clinical trials for GBS, the third assay in the ARIES pipeline," said Homi Shamir, President and CEO of Luminex. "The progression of our ARIES menu with assays that are important to patient care continues and the Group B Strep assay is a key contributor due to the high prevalence and potentially serious or life threatening consequences to newborns."

The clinical trials for the ARIES GBS Assay are being conducted at several clinical laboratories in the U.S., and Luminex still expects its FDA submission for the ARIES platform and ARIES HSV 1&2 Assay to occur in the summer of 2015.

Advertisement